Glenmark Pharmaceuticals Limited (GLENMARK.BO)
INR 1541.0
(1.1%)
INR 1541.0
(1.1%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.51 Billion INR | -96.25% |
| 2022 | 40.46 Billion INR | 45.99% |
| 2021 | 27.71 Billion INR | -32.61% |
| 2020 | 41.12 Billion INR | -3.78% |
| 2019 | 42.74 Billion INR | 19.6% |
| 2018 | 35.73 Billion INR | -13.71% |
| 2017 | 41.41 Billion INR | -8.7% |
| 2016 | 45.36 Billion INR | 82.38% |
| 2015 | 24.87 Billion INR | -3.38% |
| 2014 | 25.74 Billion INR | 6.0% |
| 2013 | 24.28 Billion INR | 26.47% |
| 2012 | 19.2 Billion INR | 46.31% |
| 2011 | 13.12 Billion INR | 112.7% |
| 2010 | 6.17 Billion INR | -66.99% |
| 2009 | 18.69 Billion INR | -10.74% |
| 2008 | 20.94 Billion INR | 111.35% |
| 2007 | 9.9 Billion INR | 5.79% |
| 2006 | 9.36 Billion INR | 27.37% |
| 2005 | 7.35 Billion INR | 68.1% |
| 2004 | 4.37 Billion INR | 280.83% |
| 2003 | 1.14 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 0.0% |
| 2023 FY | 1.51 Billion INR | -96.25% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 40.43 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 1.51 Billion INR | 0.0% |
| 2022 Q4 | 40.46 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 40.46 Billion INR | 45.99% |
| 2022 Q2 | 37.09 Billion INR | 0.0% |
| 2021 Q4 | 27.71 Billion INR | 0.0% |
| 2021 FY | 27.71 Billion INR | -32.61% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 26.3 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 FY | 41.12 Billion INR | -3.78% |
| 2020 Q4 | 41.12 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 25.95 Billion INR | 0.0% |
| 2019 Q2 | 31.04 Billion INR | 0.0% |
| 2019 Q4 | 42.74 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 42.74 Billion INR | 19.6% |
| 2018 Q2 | 41.2 Billion INR | 0.0% |
| 2018 FY | 35.73 Billion INR | -13.71% |
| 2018 Q4 | 35.73 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q2 | 42.47 Billion INR | 0.0% |
| 2017 Q4 | 41.41 Billion INR | 0.0% |
| 2017 FY | 41.41 Billion INR | -8.7% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 46.88 Billion INR | 0.0% |
| 2016 Q4 | 45.36 Billion INR | 0.0% |
| 2016 FY | 45.36 Billion INR | 82.38% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q4 | 24.87 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 24.87 Billion INR | -3.38% |
| 2015 Q2 | 20.64 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q2 | 23.45 Billion INR | 0.0% |
| 2014 Q4 | 25.74 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 FY | 25.74 Billion INR | 6.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 24.28 Billion INR | 26.47% |
| 2013 Q4 | 24.28 Billion INR | 0.0% |
| 2013 Q2 | 28.36 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q4 | 19.2 Billion INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 FY | 19.2 Billion INR | 46.31% |
| 2011 FY | 13.12 Billion INR | 112.7% |
| 2011 Q4 | 13.12 Billion INR | 0.0% |
| 2010 FY | 6.17 Billion INR | -66.99% |
| 2009 FY | 18.69 Billion INR | -10.74% |
| 2008 FY | 20.94 Billion INR | 111.35% |
| 2007 FY | 9.9 Billion INR | 5.79% |
| 2006 FY | 9.36 Billion INR | 27.37% |
| 2005 FY | 7.35 Billion INR | 68.1% |
| 2004 FY | 4.37 Billion INR | 280.83% |
| 2003 FY | 1.14 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 235.2 Million INR | -544.945% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -10759.894% |
| Sigachi Industries Limited | 265.79 Million INR | -470.7% |
| Bal Pharma Limited | 363.82 Million INR | -316.935% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -1258.922% |
| Medico Remedies Limited | 8.67 Million INR | -17392.043% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Venus Remedies Limited | 386.8 Million INR | -292.169% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -1322.992% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Nectar Lifesciences Limited | 1.4 Billion INR | -8.112% |
| Shilpa Medicare Limited | 5.6 Billion INR | 72.92% |
| Aarti Drugs Limited | 2.75 Billion INR | 44.906% |
| Lupin Limited | 1.55 Billion INR | 2.311% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 92.895% |
| Zydus Lifesciences Limited | 251 Million INR | -504.347% |
| Windlas Biotech Limited | 20.18 Million INR | -7416.898% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Eris Lifesciences Limited | 6.54 Billion INR | 76.824% |
| Valiant Laboratories Limited | 746.63 Million INR | -103.168% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -541.671% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | -43.335% |
| Ipca Laboratories Limited | 5.8 Billion INR | 73.865% |
| Bliss GVS Pharma Limited | 355.92 Million INR | -326.192% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -11305.338% |
| Bajaj HealthCare Limited | 650.34 Million INR | -133.247% |
| RPG Life Sciences Limited | -30.3 Million INR | 5106.304% |
| Mankind Pharma Limited | 248.67 Million INR | -509.992% |
| Laurus Labs Limited | 8.6 Billion INR | 82.37% |
| Piramal Pharma Limited | 24.83 Billion INR | 93.893% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 124538.884% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 90.543% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | -141.239% |
| Unichem Laboratories Limited | 382.22 Million INR | -296.867% |
| Sequent Scientific Limited | 1.42 Billion INR | -6.286% |
| Novartis India Limited | 50.7 Million INR | -2891.933% |
| Wanbury Limited | 820 Million INR | -84.989% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -614.324% |
| Wockhardt Limited | 8.91 Billion INR | 82.975% |
| Themis Medicare Limited | 267.74 Million INR | -466.561% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -1907.291% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 95.21% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -927.647% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 74.676% |
| Divi's Laboratories Limited | 20 Million INR | -7484.55% |
| NATCO Pharma Limited | 53 Million INR | -2762.094% |
| Gufic Biosciences Limited | 1.53 Billion INR | 1.476% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 84.974% |
| Procter & Gamble Health Limited | 68.8 Million INR | -2104.811% |
| FDC Limited | 2.46 Million INR | -61412.976% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 17.335% |
| Granules India Limited | 689.71 Million INR | -119.934% |
| Medicamen Biotech Limited | 12.55 Million INR | -11982.119% |
| Alkem Laboratories Limited | 400 Million INR | -279.228% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -5349.454% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -42450.07% |
| Megasoft Limited | 1.35 Billion INR | -11.778% |
| ZIM Laboratories Limited | 356 Million INR | -326.091% |
| Strides Pharma Science Limited | 6.71 Billion INR | 77.41% |
| Neuland Laboratories Limited | 449.2 Million INR | -237.687% |
| Morepen Laboratories Limited | 33.64 Million INR | -4409.245% |
| Hikal Limited | 4.22 Billion INR | 64.127% |
| Indoco Remedies Limited | 3.51 Billion INR | 56.873% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -379127.5% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -1035.913% |
| Hester Biosciences Limited | 1.81 Billion INR | 16.549% |